Evidence map›Paper›PMID 29991125›Full record

ArticleCancer biomarkers : section A of Disease markers2018

Activation of PI3K/AKT is involved in TINAG-mediated promotion of proliferation, invasion and migration of hepatocellular carcinoma.

Meng-Hui Zhang, Hu Niu, Zheng Li, Ren-Tao Huo, Jun-Mei Wang, Jun Liu

Abstract read
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 11 citations in OpenAlex.

  1. Genome-wide association study of dermatophytosis in the UK Biobank cohort.Journal of the European Academy of Dermatology and Venereology : JEADV · 2022
    Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Celastrol Enhances the Anti-Liver Cancer Activity of Sorafenib.Medical science monitor : international medical journal of experimental and clinical research · 2019
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Meng-Hui ZhangDepartment of Hepatobiliary, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250000, Shandong, China.
Hu NiuDepartment of General Surgery, The Fourth People's Hospital of Jinan, Jinan 250031, Shandong, China.
Zheng LiDepartment of General Surgery, The Fourth People's Hospital of Jinan, Jinan 250031, Shandong, China.
Ren-Tao HuoDepartment of General Surgery, The Fourth People's Hospital of Jinan, Jinan 250031, Shandong, China.
Jun-Mei WangHeze Traditional Chinese Medicine Hospital, Heze 274035, Shandong, China.
Jun LiuDepartment of Hepatobiliary, Shandong Provincial Hospital Affiliated to Shandong University, Jinan 250000, Shandong, China.
Fourth People’s Hospital of Jinan · CNThe Fourth People's Hospital · CNHeze Municipal Hospital · CNShandong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveHepatocellular carcinoma (HCC) is a highly aggressive malignancy that has a poor prognosis. Through the literatures, TINAG significantly participated in the processes of the renal-associated diseases, but there were no studies about the roles of TINAG in the HCC development. Hence, we attempted to use the HCC samples collected by ourselves to reveal the clinical significance and prognostic impact of TINAG in HCC.

methodsWe first measured the expression level of TINAG in HCC on the basis of TCGA database. Then, real time quantitative reverse transcription PCR (RT-qPCR) was used to examine the expression level of TINAG in 100 pairs of HCC tissues and corresponding adjacent non-tumor tissues, as well as HCC cell lines (HepG2, HB611, HHCC, and Hep3B). Moreover, Kaplan-Meier method and COX's proportional hazards model were utilized to perform the survival and prognosis analyses using the clinical data collected by ourselves. After knockdown of TINAG, the cell proliferation, invasion and migration capacities of HepG2 and Hep3B cells were evaluate by counting kit-8 (CCK-8) assay (24 h, 48 h, 72 h, and 96 h post-cultivation), clone formation experiment, would-healing, and invasion as well as migration assays. To further explore whether the dys-regulated TINAG expression regulates the HCC progression and prognosis, protein biomarkers of PI3K signaling pathway, including AKT, p-AKT, PI3K, p-PI3K, p70S6K, and p-p70S6K were measured based on western blotting analysis.

resultsAccording to the data of TCGA database, clinical patients, and HCC cell lines, TINAG was highly expressed in HCC compared with normal. Relationship of TINAG expression level with the clinicopathological factors implicated that the high expression of TINAG was significantly associated with pathologic stage, pathologic-node, and pathologic-metastasis. Univariate as well as multivariate COX analysis indicated that TINAG expression and pathologic metastasis can serve as the independent prognostic factor for overall survival of HCC. After TINAG knockdown in HepG2 and Hep3B cells, cell proliferation rate, the colony numbers, and the invasive and migratory capacity were found to be suppressed. Remarkably, western blot results showed that reduction of TINAG remarkably decreased p-AKT, p-PI3K, and p-p70S6K expression level in HepG2 and Hep3B cells.

conclusionCollectively, our results underscore the significance of TINAG in HCC progression and prognosis, and TINAG might be a novel candidate oncogene in HCC. These results propose that targeting TINAG might offer future clinical utility in HCC.

Indexed as

AgedBiomarkers, TumorCarcinoma, HepatocellularCell Adhesion MoleculesCell MovementCell ProliferationFemaleGene Expression Regulation, NeoplasticHep G2 CellsHumansLiver NeoplasmsMaleMiddle AgedNeoplasm InvasivenessOncogene Protein v-aktPhosphatidylinositol 3-KinasesBiomarkers, TumorCell Adhesion MoleculesOncogene Protein v-aktPhosphatidylinositol 3-KinasesTINAG protein, humanhepatocellular carcinomainvasionmigrationproliferationTINAG

Identifiers

PMID29991125
PMCPMC13078558
OpenAlexW2810181636

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.